Home / Stock ratings / Healthcare Stocks / CVS
Stock rating · Retail-Drug Stores and Proprietary Stores
CVS Health Corporation (CVS) Stock Rating & Analysis
As of October 7, 2026, MELANY rates CVS Health Corporation 68 out of 100 (Favorable). Its highest factor score is earnings track record at 92, and its lowest is business quality at 29.
MELANY ratingRated 2026-10-07CVS · composite score
About CVS Health Corporation
CVS Health provides a range of healthcare services. Rooted in retail pharmacy, it runs roughly 9,000 stores, mostly in the US. Through Caremark it is a large pharmacy benefit manager processing about 2 billion adjusted claims a year, and through Aetna it operates a major health insurer serving about 27 million medical members. Its Oak Street Health acquisition added primary care.
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How CVS's rating has moved
- -3Past week, since Sep 30: score fell 3 points to 68.
- -3Past four weeks, since Sep 9: score fell 3 points to 68.
Weekly points: Sep 9: 71 · Sep 16: 71 · Sep 23: 72 · Sep 30: 71 · Oct 7: 68 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why CVS scores 68/100
CVS's 8 factor scores run from 29 to 92, and 5 of them sit above its composite of 68. Here is how CVS breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 10.2x, earnings growth accelerating
- PEG ratio 0.20 (< 1 = undervalued)
- FCF yield 7.3%
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +20%
- Earnings in 28 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Analyst targets 34% upside
Near-term events that could move the stock.
- Earnings in 28 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How CVS compares
As of October 7, 2026, CVS Health Corporation ranks 9th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for CVS
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
CVS Health Corporation sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds CVS's momentum and catalyst factors above.
CVS trade plan (Pro)
MELANY has a full position plan for CVS Health Corporation: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates CVS
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. CVS Health Corporation's 68/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CVS
Is CVS Health Corporation (CVS) a buy?
As of 2026-10-07, MELANY rated CVS Health Corporation Favorable with a composite score of 68/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is CVS Health Corporation's MELANY score?
CVS Health Corporation (CVS) has a MELANY composite score of 68/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the CVS stock rating calculated?
MELANY scores CVS from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy CVS Health Corporation stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates CVS Health Corporation (CVS) Favorable with a composite of 68/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CVS stock price forecast?
MELANY does not publish price targets or forecasts for CVS. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 68/100 across eight factors for CVS Health Corporation, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CVS stock overvalued or undervalued?
MELANY's valuation factor currently reads 80/100 for CVS Health Corporation, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CVS's read.
What price should I buy CVS at?
Rather than chasing the current price, MELANY computes a smart entry zone for CVS: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying CVS stock?
The top risks MELANY currently flags for CVS Health Corporation: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is CVS Health Corporation a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 29/100 for CVS Health Corporation, and earnings track record, at 92/100. The 68/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CVS stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 55/100 for CVS right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CVS rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CVS continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, CVS included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.